-DigiTimes Alert
Cadrenal Therapeutics Appoints Jeff Cole As Chief Operating Officer In Advance Of Tecarfarin Phase 3 Pivotal Trial
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a biopharmaceutical company developing tecarfarin, a novel Vitamin K Antagonist (VKA) for unmet needs in anticoagulation (blood thinning) therapy, today announced the